NASDAQ:CNAT - Conatus Pharmaceuticals Stock Price, Price Target & More

Conatus Pharmaceuticals trades on the NASDAQ under the ticker symbol "CNAT."

Conatus Pharmaceuticals Inc (NASDAQ:CNAT) posted its earnings results on Wednesday, May, 2nd. The biotechnology company reported ($0.17) earnings per share for the quarter, meeting the Zacks' consensus estimate of ($0.17). The biotechnology company had revenue of $9.74 million for the quarter, compared to analyst estimates of $8.88 million. Conatus Pharmaceuticals had a negative return on equity of 64.30% and a negative net margin of 49.30%. View Conatus Pharmaceuticals' Earnings History.

Conatus Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, August, 1st 2018. View Earnings Estimates for Conatus Pharmaceuticals.

6 brokerages have issued 1 year target prices for Conatus Pharmaceuticals' shares. Their forecasts range from $4.30 to $20.00. On average, they anticipate Conatus Pharmaceuticals' stock price to reach $12.1414 in the next twelve months. This suggests a possible upside of 175.3% from the stock's current price. View Analyst Ratings for Conatus Pharmaceuticals.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Conatus Pharmaceuticals in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Conatus Pharmaceuticals saw a decrease in short interest in June. As of June 29th, there was short interest totalling 1,612,627 shares, a decrease of 32.0% from the June 15th total of 2,372,503 shares. Based on an average trading volume of 809,565 shares, the short-interest ratio is currently 2.0 days. Approximately 6.1% of the company's shares are short sold. View Conatus Pharmaceuticals' Current Options Chain.

Some companies that are related to Conatus Pharmaceuticals include Merus (MRUS), Keryx Biopharmaceuticals (KERX), Depomed (DEPO), Magenta Therapeutics (MGTA), ArQule (ARQL), Arcus Biosciences (RCUS), Rigel Pharmaceuticals (RIGL), Stemline Therapeutics (STML), Aurinia Pharmaceuticals (AUPH), Evolus (EOLS), Cytokinetics (CYTK), Verastem (VSTM), ZEALAND PHARMA/S (ZEAL), Forty Seven (FTSV) and Lannett (LCI).

Headlines about CNAT stock have been trending somewhat positive recently, Accern Sentiment reports. Accern identifies negative and positive press coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Conatus Pharmaceuticals earned a daily sentiment score of 0.24 on Accern's scale. They also assigned news stories about the biotechnology company an impact score of 46.73 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the next few days.

Shares of CNAT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of CNAT stock can currently be purchased for approximately $4.41.

Conatus Pharmaceuticals has a market capitalization of $132.58 million and generates $35.38 million in revenue each year. The biotechnology company earns $-17,390,000.00 in net income (profit) each year or ($0.61) on an earnings per share basis. Conatus Pharmaceuticals employs 35 workers across the globe.

Conatus Pharmaceuticals' mailing address is 16745 WEST BERNARDO DRIVE Suite 200, San Diego CA, 92127. The biotechnology company can be reached via phone at 858-376-2600 or via email at [email protected]